UNSPSC 51361604: Romifidine

This classification denotes a serotonin agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 876351L05K. European Medicines Agency schedules Romifidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10374MIG. Romifidine generally arises in the molecular formula C9H9BRFN3.

The term ROMIFIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) ROMIFIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule romifidine under HS 29332990 and SITC 51573. As of Q4 2014, ROMIFIDINE remains the US FDA Preferred Term for this commodity. Romifidine bears US NLM identifiers UMLS ID C0171473 and NCI Concept Code C74389. SMILES: BRC1C(NC2=NCCN2)C(F)CCC1.

UNSPSC 51361604 Romifidine is a Commodity code that nominally covers a specific sedative pharmaceutical, yet recent state and local procurement activity tagged under this code shows minimal direct alignment with romifidine procurement itself. Instead, the code appears in solicitations for broader pharmaceutical supply agreements, including naloxone distribution, generic multi-source pharmaceuticals and over-the-counter products, and prescription program infrastructure. The work being solicited reflects state and local health agencies' need to source pharmaceutical products and support systems through competitive bidding and cooperative purchasing vehicles, often with defined delivery schedules, compliance certifications, and quality assurance requirements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and state-administered cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving multiple states including Oregon). These entities typically require vendors to maintain cGMP and Drug Supply Chain Security Act compliance, carry substantial insurance coverage, utilize E-Verify, and demonstrate pricing flexibility across multiple net-price and discount models.

Recent activity spans Florida, Texas, and Minnesota-administered multistate purchasing, with the most visible opportunities including Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (response deadline July 26, 2023), Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities (due March 26, 2026, with awards effective July 1, 2026). The mismatch between the code's nominal pharmaceutical product and the actual scope of recent solicitations suggests either tagging inconsistency or that romifidine procurement itself sees limited recent state and local demand. Vendors pursuing opportunities under this code should expect cooperative purchasing and multistate consortium vehicles, mandatory wholesaler relationships, detailed product and NDC code documentation, and performance penalties for reporting or onboarding delays.